Atara Biotherapeutics annual debt-to-equity ratio
2017
2018
2019
2020
2021
2022
2023
Atara Biotherapeutics Debt-to-Equity Ratio Growth & History (ATRA)
Atara Biotherapeutics's debt-to-equity ratio was 0.61 for fiscal 2023.
View full Atara Biotherapeutics company overviewAtara Biotherapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | 0.61 | 0.01 | +2.45% |
| 2022 | 2022-12-31 | 0.59 | 0.49 | +487.85% |
| 2021 | 2021-12-31 | 0.10 | 0.07 | +208.36% |
| 2020 | 2020-12-31 | 0.03 | −0.02 | −40.20% |
| 2019 | 2019-12-31 | 0.05 | 0.05 | +2423.02% |
| 2018 | 2018-12-31 | 0.00 | −0.00 | −64.04% |
| 2017 | 2017-12-31 | 0.01 | — | — |
Atara Biotherapeutics quarterly debt-to-equity ratio
Q4.17
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | 0.61 | 0.01 | +2.45% |
| Q2 2023 | 2023-06-30 | 8.68 | 8.37 | +2712.49% |
| Q1 2023 | 2023-03-31 | 1.04 | 0.96 | +1236.07% |
| Q4 2022 | 2022-12-31 | 0.59 | 0.49 | +487.85% |
| Q3 2022 | 2022-09-30 | 0.41 | 0.33 | +417.32% |
| Q2 2022 | 2022-06-30 | 0.31 | 0.27 | +740.03% |
| Q1 2022 | 2022-03-31 | 0.08 | 0.05 | +147.01% |
| Q4 2021 | 2021-12-31 | 0.10 | 0.07 | +208.36% |
| Q3 2021 | 2021-09-30 | 0.08 | 0.04 | +113.60% |
| Q2 2021 | 2021-06-30 | 0.04 | 0.00 | +4.35% |
| Q1 2021 | 2021-03-31 | 0.03 | −0.02 | −42.33% |
| Q4 2020 | 2020-12-31 | 0.03 | −0.02 | −40.20% |
| Q3 2020 | 2020-09-30 | 0.04 | −0.01 | −26.56% |
| Q2 2020 | 2020-06-30 | 0.04 | −0.04 | −50.08% |
| Q1 2020 | 2020-03-31 | 0.05 | −0.00 | −1.35% |
| Q4 2019 | 2019-12-31 | 0.05 | 0.05 | +2423.02% |
| Q3 2019 | 2019-09-30 | 0.05 | — | — |
| Q2 2019 | 2019-06-30 | 0.07 | — | — |
| Q1 2019 | 2019-03-31 | 0.06 | — | — |
| Q4 2018 | 2018-12-31 | 0.00 | −0.00 | −64.04% |
| Q4 2017 | 2017-12-31 | 0.01 | — | — |
Atara Biotherapeutics debt-to-equity ratio trends
Over the last five fiscal years, Atara Biotherapeutics's debt-to-equity ratio increased from 0.00 to 0.61, a change of 0.61. The latest reported quarter, Q4 2023, shows 0.61.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atara Biotherapeutics source filings ↗